Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
BackgroundTaxane, carboplatin and trastuzumab (TCH) is an effective neoadjuvant regimen for human epidermal growth factor Number Holders receptor 2 (HER2)-positive breast cancer with high pathologic complete response (pCR) rate.The KATHERINE trial changes the outlook for high-risk HER2-positive breast cancer, which suggests that escalation treatmen